RxDoctor Payments Data

Adeela Alizai, MD

Ophthalmology · Mishawaka, INNPI 1306852520

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 24 payments — averaging $53.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Straumann USA LLC$366
  • Amgen$353
  • Alcon$189
  • AstraZeneca$159
  • GSK$100
  • Harrow Eye, LLC$35
  • plus $86 from 4 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,27699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Straumann USA LLC1$366
Amgen(2 entities)11$353
Alcon3$189
AstraZeneca3$159
GSK1$100
Harrow Eye, LLC1$35
Spark Therapeutics, Inc.1$29
Novo Nordisk1$23
Dompe US, Inc.1$20
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,288 in reported general payments places this provider in the 45th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$14,798
Medicare patients
35
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MoxifloxacinMoxifloxacin Hcl12$374

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →